NASDAQ:SNDX Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis $19.84 +0.76 (+3.98%) As of 08/14/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Syndax Pharmaceuticals Stock (NASDAQ:SNDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Syndax Pharmaceuticals alerts:Sign Up Key Stats Today's Range$18.82▼$19.8650-Day Range$16.96▼$24.8452-Week Range$12.99▼$25.59Volume1.25 million shsAverage Volume1.37 million shsMarket Capitalization$1.76 billionP/E RatioN/ADividend YieldN/APrice Target$41.91Consensus RatingModerate Buy Company Overview Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology. The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications. Entinostat is currently in Phase 3 development in combination with pembrolizumab for patients with hormone receptor-positive, HER2-negative advanced breast cancer. Syndax’s pipeline also includes SNDX-5613 (revumenib), a menin inhibitor targeting acute leukemias harboring MLL rearrangements or NPM1 mutations, which is advancing through Phase 2 clinical trials. In addition to these core programs, Syndax is exploring combination strategies to maximize clinical benefit and address resistance mechanisms. The company was founded in 2002 and has cultivated collaborations with leading academic institutions and industry partners to accelerate development and broaden the reach of its therapies. Syndax operates primarily in the United States but plans to expand its global footprint through strategic partnerships and licensing agreements. Under the leadership of President and Chief Executive Officer Daniel A. Swisher and Chief Financial Officer Wolfgang R. Grosse, Syndax continues to build a pipeline designed to deliver meaningful improvements in outcomes for cancer patients worldwide.AI Generated. May Contain Errors. Read More Syndax Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreSNDX MarketRank™: Syndax Pharmaceuticals scored higher than 47% of companies evaluated by MarketBeat, and ranked 574th out of 914 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on no strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSyndax Pharmaceuticals has a consensus price target of $41.91, representing about 111.2% upside from its current price of $19.84.Amount of Analyst CoverageSyndax Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Syndax Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($1.97) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -7.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -7.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 116.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Syndax Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted26.87% of the float of Syndax Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 18.58, which indicates bearish sentiment.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently increased by 8.88%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.15 News SentimentSyndax Pharmaceuticals has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Syndax Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest1 people have searched for SNDX on MarketBeat in the last 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,120,789.00 in company stock.Percentage Held by Insiders4.80% of the stock of Syndax Pharmaceuticals is held by insiders.Percentage Held by InstitutionsSyndax Pharmaceuticals has minimal institutional ownership at this time.Read more about Syndax Pharmaceuticals' insider trading history. Receive SNDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNDX Stock News HeadlinesJPMorgan Chase & Co. Issues Pessimistic Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock PriceAugust 13 at 2:01 AM | americanbankingnews.comSyndax (SNDX) Q2 2026 Earnings Call TranscriptAugust 11, 2026 | finance.yahoo.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.August 16 at 1:00 AM | Paradigm Press (Ad)Q3 EPS Forecast for Syndax Pharmaceuticals Cut by AnalystAugust 9, 2026 | americanbankingnews.comHow Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) InvestorsAugust 8, 2026 | finance.yahoo.comHC Wainwright Issues Pessimistic Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock PriceAugust 7, 2026 | americanbankingnews.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)August 5, 2026 | globenewswire.comSyndax Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call PresentationAugust 5, 2026 | seekingalpha.comSee More Headlines SNDX Stock Analysis - Frequently Asked Questions How have SNDX shares performed this year? Syndax Pharmaceuticals' stock was trading at $21.01 at the start of the year. Since then, SNDX stock has decreased by 5.6% and is now trading at $19.84. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) released its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.10. The company's revenue for the quarter was up 91.8% compared to the same quarter last year. Read the conference call transcript. When did Syndax Pharmaceuticals IPO? Syndax Pharmaceuticals (SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. Who are Syndax Pharmaceuticals' major shareholders? Syndax Pharmaceuticals' top institutional investors include BlackRock Inc. (10.18%), Elmind Capital LP (2.09%), Trails Edge Capital Partners LP (1.25%) and Algert Global LLC (1.19%). Insiders that own company stock include Michael A Metzger, Dennis Podlesak, Keith A Goldan, Neil Gallagher and Nicholas AJ Botwood. View institutional ownership trends. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Syndax Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and ServiceNow (NOW). Company Calendar Last Earnings8/04/2026Today8/16/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 SNDX's financial health is in the Green zone, according to TradeSmith. SNDX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SNDX CIK1395937 Webwww.syndax.com Phone(781) 419-1400Fax781-419-1420Employees110Year Founded2005Price Target and Rating Average Price Target for Syndax Pharmaceuticals$41.91 High Price Target$57.00 Low Price Target$34.00 Potential Upside/Downside+111.2%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($2.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$285.42 million Net Margins-87.52% Pretax Margin-87.52% Return on Equity-372.94% Return on Assets-39.11% Debt Debt-to-Equity Ratio38.95 Current Ratio6.77 Quick Ratio6.44 Sales & Book Value Annual Sales$172.35 million Price / Sales10.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book116.71Miscellaneous Outstanding Shares88,610,000Free Float84,357,000Market Cap$1.76 billion OptionableOptionable Beta0.40 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:SNDX) was last updated on 8/16/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredA Dark Day Is Coming to AmericaKeith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...TradeSmith | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredWhat is Trump’s decade-long obsession?No president has moved markets like Trump, adding and erasing trillions in value seemingly at will. Analyst...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNDX Stock Alerts